Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Amyloid beta protein

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    11 result(s) found for: Amyloid beta protein. Displaying page 1 of 1.
    EudraCT Number: 2011-000794-31 Sponsor Protocol Number: October2011,version5 Start Date*: 2011-06-15
    Sponsor Name:Dept. of Pharmacology
    Full Title: Neurodegenerative Changes in Alzheimer’s Disease: Identifying potential effects of Victoza® on degenerative changes
    Medical condition: Alzheimer's disease
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-002744-25 Sponsor Protocol Number: RK100.1 Start Date*: 2006-06-29
    Sponsor Name:Roskamp Institute
    Full Title: An open label evaluation of the safety and efficacy of nilvadipine in mild to moderate Alzheimer's Disease
    Medical condition: Alzheimer's disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005542-38 Sponsor Protocol Number: MK-8931-019 Start Date*: 2014-03-17
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,
    Full Title: A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects with Amnestic Mild Cognitive Impairment...
    Medical condition: prodromal Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004852 10001897 Alzheimer's disease (incl subtypes) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Prematurely Ended) ES (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended) DE (Completed) GB (Prematurely Ended) FI (Completed) NL (Prematurely Ended) BE (Completed) HU (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-004274-41 Sponsor Protocol Number: 54861911ALZ2004 Start Date*: 2015-05-29
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Randomized, Two-Period, Double-Blind Placebo-Controlled and Open-Label, Multicenter Extension Study to Determine the Long-Term Safety and Tolerability of JNJ-54861911 in Subjects in the Early Alz...
    Medical condition: Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) SE (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) FR (Completed) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-005220-15 Sponsor Protocol Number: IIS-1-025R-NL_Kamphuisen Start Date*: 2013-10-23
    Sponsor Name:University Medical Center Groningen
    Full Title: Off taRget Effects of Linagliptin monothErapy on Arterial Stiffness in Early diabetes
    Medical condition: type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004861 10045252 Type II diabetes mellitus without mention of complication LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-003435-31 Sponsor Protocol Number: CL-758010 Start Date*: 2006-02-03
    Sponsor Name:Neurochem Inc.
    Full Title: A Phase III Study of the Efficacy and Safety of Alzhemed™ as Add-on Therapy in Mild to Moderate Alzheimer's Disease Patients.
    Medical condition: Alzheimer’s Disease (AD) is an irreversible, progressive neuro-degenartive disorder, characterized by gradual cognitive deficits associated with abnormal behaviour, personality changes, and which u...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Prematurely Ended) BE (Completed) SE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-005118-37 Sponsor Protocol Number: H6L-MC-LFAN (e) Start Date*: 2008-12-15
    Sponsor Name:Eli Lilly and Company
    Full Title: Effect of γ-Secretase Inhibition on the Progression of Alzheimer’s Disease: LY450139 versus Placebo
    Medical condition: Alzheimers Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) FR (Completed) FI (Completed) ES (Prematurely Ended) DE (Prematurely Ended) BE (Completed) GR (Prematurely Ended) SE (Prematurely Ended) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-004974-16 Sponsor Protocol Number: IL1ra03 Start Date*: 2018-11-08
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge
    Full Title: DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMISED CLINICAL DOSE-RANGING STUDY TREATING MODERATE-SEVERE TRAUMATIC BRAIN INJURY PATIENTS WITH RECOMBINANT HUMAN INTERLEUKIN 1 RECEPTOR ANTAGONIST.
    Medical condition: We wish to study the drug Kineret in patients suffering from moderate-to-severe traumatic brain injury
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004863 10060690 Traumatic brain injury LLT
    20.1 10029205 - Nervous system disorders 10051288 Central nervous system inflammation PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-003151-20 Sponsor Protocol Number: 8931-017 Start Date*: 2013-01-04
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Randomized, Placebo Controlled, Parallel-Group, Double Blind Efficacy and Safety Trial of MK-8931 in Subjects with Mild to Moderate Alzheimer?s Disease. (Phase 2/3; Protocol No. MK-8931-017-02) ...
    Medical condition: mild to moderate Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) NL (Completed) GB (Completed) IT (Prematurely Ended) DE (Completed) PT (Completed) HU (Completed) BE (Completed) AT (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-005755-20 Sponsor Protocol Number: ALZ-801-AD301 Start Date*: 2021-06-21
    Sponsor Name:Alzheon, Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects with Early Alzheimer's Disease and APOE4/4 Genotype
    Medical condition: Early Alzheimer’s Disease (AD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001897 Alzheimer's disease (incl subtypes) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) NL (Completed) ES (Completed) CZ (Completed) IS (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000709-10 Sponsor Protocol Number: UKM12_0026 Start Date*: 2014-12-19
    Sponsor Name:Universitätsklinikum Münster
    Full Title: Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential
    Medical condition: relapsing-remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 16 14:50:43 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA